Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.7 CHF | +1.24% | +3.04% | +15.30% |
May. 03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.30% | 536M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US